Can docetaxel plus estramustine prolong the survival of men with metastatic hormone-refractory prostate cancer?

Avishay Sella

doi:10.1038/ncpuro0064

Can docetaxel plus estramustine prolong the survival of men with metastatic hormone-refractory prostate cancer?

Research output: Contribution to journal › Short survey › peer-review

Original language	English
Pages (from-to)	18-19
Number of pages	2
Journal	Nature Clinical Practice Urology
Volume	2
Issue number	1
DOIs	https://doi.org/10.1038/ncpuro0064
State	Published - Jan 2005
Externally published	Yes

Keywords

Androgen-independent
Docetaxel
Estramustine
Prostate cancer
Survival

Access to Document

10.1038/ncpuro0064

Cite this

@article{9132348acf564dfabb0f7c095c638c62,

title = "Can docetaxel plus estramustine prolong the survival of men with metastatic hormone-refractory prostate cancer?",

keywords = "Androgen-independent, Docetaxel, Estramustine, Prostate cancer, Survival",

author = "Avishay Sella",

year = "2005",

month = jan,

doi = "10.1038/ncpuro0064",

language = "אנגלית",

volume = "2",

pages = "18--19",

journal = "Nature Clinical Practice Urology",

issn = "1743-4270",